Farther Finance Advisors LLC Buys 2,028 Shares of Twist Bioscience Co. (NASDAQ:TWST)

Farther Finance Advisors LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 59.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 5,429 shares of the company’s stock after buying an additional 2,028 shares during the period. Farther Finance Advisors LLC’s holdings in Twist Bioscience were worth $252,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $34,000. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock valued at $34,000 after purchasing an additional 267 shares in the last quarter. US Bancorp DE boosted its position in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience during the 3rd quarter valued at about $95,000. Finally, KBC Group NV boosted its position in shares of Twist Bioscience by 71.4% during the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock valued at $137,000 after purchasing an additional 1,226 shares in the last quarter.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 2,402 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the completion of the sale, the chief executive officer now directly owns 662,692 shares of the company’s stock, valued at approximately $27,110,729.72. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Adam Laponis sold 5,886 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares of the company’s stock, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 33,804 shares of company stock valued at $1,601,404. 3.01% of the stock is owned by insiders.

Analyst Ratings Changes

TWST has been the topic of several research analyst reports. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research report on Tuesday, November 26th. Robert W. Baird upped their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Finally, Wolfe Research assumed coverage on Twist Bioscience in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $54.40.

Twist Bioscience Stock Performance

Shares of Twist Bioscience stock opened at $40.57 on Wednesday. The company has a market cap of $2.42 billion, a PE ratio of -12.00 and a beta of 2.15. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The business has a 50 day moving average price of $45.54 and a 200-day moving average price of $45.25. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.75) earnings per share. Equities analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current fiscal year.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.